Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, reveals current regulatory challenges in the U.S. for drug approvals, how a one-sized-fits-all approach to marketing and global launches no longer works, and when a global launch may be advantageous.
Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies.
In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including:
Join Meg Rivers, managing editor, as she dives into this topic with Cope.
Torrey Cope is a partner in Sidley’s food, drug, and medical device practice group. An experienced regulatory lawyer with scientific training, he has a passion for helping pharmaceutical, biotechnology, and medical technology companies solve their most challenging regulatory problems, whether they involve clinical trials, marketing authorization, promotion, product safety, or other issues. Many of his clients are working at the forefront of life sciences innovation in fields such as immunotherapy, regenerative medicine, genetic testing/next-generation sequencing, digital health, and artificial intelligence/machine learning.
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.